Market Exclusive

Analyst Activity – Cantor Fitzgerald Reiterates Buy on Cidara Therapeutics (NASDAQ:CDTX)

Analyst Ratings For Cidara Therapeutics (NASDAQ:CDTX)

Today, Cantor Fitzgerald reiterated its Buy rating on Cidara Therapeutics (NASDAQ:CDTX) with a price target of $15.00.

Some recent analyst ratings include

Recent Insider Trading Activity For Cidara Therapeutics (NASDAQ:CDTX)
Cidara Therapeutics (NASDAQ:CDTX) has insider ownership of 18.90% and institutional ownership of 55.45%.

Recent Trading Activity for Cidara Therapeutics (NASDAQ:CDTX)
Shares of Cidara Therapeutics closed the previous trading session at with 7.25 shares trading hands.

Exit mobile version